2 hours ago
2
Jonathan Ponciano, The Motley Fool
Sat, May 23, 2026 astatine 3:48 PM CDT 4 min read
On May 15, 2026, Prosight Management disclosed a bargain of 180,367 shares of Nektar Therapeutics (NASDAQ:NKTR), an estimated $10.27 cardinal commercialized based connected quarterly mean pricing.
What happened
What other to cognize
-
Prosight Management was a nett purchaser successful Nektar Therapeutics this quarter. The post-trade involvement accounted for 8.67% of its 13F reportable AUM.
-
Top 5 money holdings aft the filing:
-
NASDAQ: NKTR: $52.88 cardinal (8.7% of AUM)
-
NYSE: BSX: $49.92 cardinal (8.2% of AUM)
-
NASDAQ: JANX: $49.34 cardinal (8.1% of AUM)
-
NASDAQ: PRCT: $48.64 cardinal (8.0% of AUM)
-
NASDAQ: LKFT: $46.50 cardinal (7.6% of AUM)
-
-
As of May 14, 2026, shares of Nektar Therapeutics were priced astatine $66.61, up astir 600% implicit the past twelvemonth and importantly outperforming the S&P 500, which is alternatively up astir 28%.
Company overview
| Price (as of Friday) | $66.61 |
| Market capitalization | $2.25 billion |
| Revenue (TTM) | $55.63 million |
| Net income (TTM) | ($158.10 million) |
Company snapshot
-
Nektar develops biopharmaceutical products targeting unmet aesculapian needs, with a pipeline including Bempegaldesleukin (IL-2 pathway agonist), NKTR-358 (cytokine Treg stimulant), and NKTR-255 (IL-15 receptor agonist), among others.
-
The steadfast operates a research-driven concern exemplary focused connected cause discovery, objective development, and strategical collaborations with large pharmaceutical companies to make gross done licensing, milestones, and imaginable merchandise sales.
-
It serves healthcare providers, hospitals, and pharmaceutical partners, targeting patients with cancer, autoimmune, and inflammatory diseases successful the United States and planetary markets.
Nektar Therapeutics is simply a biotechnology institution specializing successful the improvement of caller therapeutics for oncology and immunology indications. The institution leverages proprietary cause find platforms and strategical partnerships to beforehand a divers objective pipeline. Its absorption connected innovative biologics and collaborative R&D positions it to code important unmet needs successful the planetary healthcare market.
What this transaction means for investors
Nektar banal has already delivered eye-popping gains implicit the past year, yet Prosight inactive chose to adhd to what has go its largest disclosed position. With that successful mind, the acquisition yet looks similar a ballot of assurance successful Nektar arsenic it approaches a make-or-break agelong of objective development.
Meanwhile, the halfway communicative remains rezpegaldesleukin, Nektar's experimental attraction for autoimmune diseases. Management precocious reported encouraging semipermanent information successful some atopic dermatitis and alopecia areata and expects to statesman its Phase 3 ZENITH-AD programme by July. The institution besides plans an End-of-Phase 2 gathering with the FDA for alopecia areata this quarter.
Financially, Nektar appears acold amended positioned than galore clinical-stage biotech peers. First-quarter gross roseate to $10.9 cardinal from $10.5 cardinal 1 twelvemonth prior, portion currency and marketable securities reached $731.6 cardinal astatine quarter-end. Management noted that the fig excludes astir $351 cardinal of nett proceeds from an April banal offering, giving the institution much than $1 cardinal successful liquidity to money development.
Ultimately, if rezpegaldesleukin succeeds successful late-stage trials, today's valuation could look conservative, but if it stumbles, overmuch of the caller rally could rapidly unwind. Prosight's acquisition suggests it believes the likelihood favour the former.
English (CA) · 
English (US) · 
Spanish (MX) ·